Amundi
ALNY icon

Amundi’s Alnylam Pharmaceuticals ALNY Stock Holding History

Amundi’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$186M Sell
617,471
-130,073
-17% -$39.2M 0.04% 322
2026
Q1 		$247M Buy
747,544
+138,665
+23% +$47.2M 0.07% 248
2025
Q4 		$242M Buy
608,879
+224,607
+58% +$99.4M 0.07% 296
2025
Q3 		$174M Sell
384,272
-9,907
-3% -$4.03M 0.06% 289
2025
Q2 		$130M Sell
394,179
-60,816
-13% -$16.8M 0.04% 363
2025
Q1 		$119M Sell
454,995
-41,306
-8% -$10.6M 0.04% 364
2024
Q4 		$119M Sell
496,301
-97,019
-16% -$25.5M 0.04% 386
2024
Q3 		$161M Sell
593,320
-143,970
-20% -$37.5M 0.06% 298
2024
Q2 		$183M Sell
737,290
-8,774
-1% -$1.39M 0.07% 252
2024
Q1 		$108M Buy
746,064
+34,372
+5% +$5.73M 0.05% 360
2023
Q4 		$141M Buy
711,692
+97,333
+16% +$16.6M 0.06% 309
2023
Q3 		$103M Sell
614,359
-60,409
-9% -$11.5M 0.05% 354
2023
Q2 		$128M Buy
674,768
+20,988
+3% +$4.16M 0.06% 315
2023
Q1 		$131M Sell
653,780
-13,753
-2% -$2.89M 0.07% 289
2022
Q4 		$150M Sell
667,533
-528,376
-44% -$113M 0.08% 261
2022
Q3 		$240M Buy
1,195,909
+289,375
+32% +$55.2M 0.14% 164
2022
Q2 		$126M Buy
906,534
+31,584
+4% +$4.48M 0.1% 228
2022
Q1 		$142M Buy
874,950
+620,695
+244% +$94.6M 0.1% 236
2021
Q4 		$37.6M Sell
254,255
-6,114
-2% -$1.14M 0.02% 538
2021
Q3 		$49.2M Buy
260,369
+46,060
+21% +$8.64M 0.03% 451
2021
Q2 		$36.3M Buy
+214,309
New +$31.4M 0.03% 521

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Amundi's ALNY Position: Q2 2026 in Review

Amundi reduced its Alnylam Pharmaceuticals (ALNY) stake by 17% in Q2 2026, selling an estimated $39.2M and leaving 617,471 shares worth $186M. The position accounts for 0.04% of the portfolio, ranked #322.

Amundi first reported a position in ALNY in Q2 2021 and has held it in 21 quarters since. The position peaked at $247M in Q1 2026. 789 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • Amundi held 617,471 shares of Alnylam Pharmaceuticals worth $186M as of Q2 2026.
  • Amundi sold 130,073 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $39.2M.
  • Alnylam Pharmaceuticals made up 0.04% of Amundi's portfolio in Q2 2026, its #322 holding.
  • Amundi first reported a position in Alnylam Pharmaceuticals in Q2 2021 and has held it in 21 quarters since.
  • Amundi's Alnylam Pharmaceuticals position peaked at $247M in Q1 2026.
  • 789 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Amundi's 13F filing for Q2 2026, filed 11 Aug 2026.